Zevra (ZVRA) CCO Joshua Schafer sells 10,500 shares under 10b5-1 plan

Rhea-AI Filing Summary

Zevra Therapeutics’ Chief Commercial Officer Joshua Schafer reported a pre-planned stock sale. On 02/03/2026, he sold 10,500 shares of Zevra Therapeutics common stock at a weighted average price of $9.1905 per share under a Rule 10b5-1(c) trading plan adopted on 03/27/2025. After this sale, he beneficially owned 62,278 shares held directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schafer Joshua

(Last) (First) (Middle)

C/O ZEVRA THERAPEUTICS, INC.

1180 CELEBRATION BOULEVARD, SUITE 103

(Street)

CELEBRATION FL 34747

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ZEVRA THERAPEUTICS, INC. [ ZVRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CCO

3. Date of Earliest Transaction (Month/Day/Year)
02/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/03/2026		S(1)		10,500	D	$9.1905(2)	62,278	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Adoption date of referenced 10b5-1(c) plan is: 3/27/2025.

2. This transaction was executed in multiple trades at prices ranging from $8.92 to $9.55. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

	/s/ Timothy J. Sangiovanni, Attorney-in-Fact for Joshua Schafer	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Zevra Therapeutics (ZVRA) report for Joshua Schafer?

Zevra Therapeutics reported that Chief Commercial Officer Joshua Schafer sold 10,500 shares of common stock. The transaction occurred on 02/03/2026 and was reported on a Form 4 insider filing, detailing the size, price, and remaining share ownership after the sale.

At what price did Joshua Schafer sell Zevra Therapeutics (ZVRA) shares?

Joshua Schafer’s sale was executed at a weighted average price of $9.1905 per share. The Form 4 notes multiple trades occurred in a price range from $8.92 to $9.55, with the reported figure representing the volume-weighted average sale price.

How many Zevra Therapeutics (ZVRA) shares does Joshua Schafer own after the reported sale?

Following the 10,500-share sale, Joshua Schafer beneficially owned 62,278 shares of Zevra Therapeutics common stock directly. This post-transaction holding amount is disclosed in Table I of the Form 4 as the total number of shares beneficially owned.

Was the Zevra Therapeutics (ZVRA) insider sale made under a 10b5-1 trading plan?

Yes. The Form 4 explains that the transaction relates to a Rule 10b5-1(c) trading plan adopted on 03/27/2025. Such pre-established trading plans allow insiders to schedule share sales in advance, following regulatory guidelines for planned transactions.

Who is the insider involved in the latest Zevra Therapeutics (ZVRA) Form 4 filing?

The insider is Joshua Schafer, Chief Commercial Officer of Zevra Therapeutics. The filing identifies him as an officer with the title CCO and reports his sale of common stock together with his remaining directly held beneficial ownership position.

How were the Zevra Therapeutics (ZVRA) insider sale trades executed on 02/03/2026?

The Form 4 notes the sale was executed in multiple trades, with prices ranging from $8.92 to $9.55 per share. The reported transaction price of $9.1905 represents the weighted average across all executed sale transactions that day.